Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
Information source: Haukeland University Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post-Polio Syndrome
Intervention: IvIg (Drug)
Phase: Phase 2/Phase 3
Sponsored by: Haukeland University Hospital
Official(s) and/or principal investigator(s):
Elisabeth Farbu, MD, PhD, Study Chair, Affiliation: Stavanger University Hospital, Stavanger, Norway
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness,
fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin
(IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical
effect of IvIg in post-polio syndrome.
Official title: Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg)
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Pain after three months
Fatigue after 3 months
Muscle strength after 3 months
Secondary outcome: Pain, Fatigue, Muscle strength after 6 months. Changes in cytokine levels in CSF and serum
Post-polio syndrome (PPS) is characterised by new muscle weakness, pain, and fatigue several
years after the attack of acute polio. This leads to increased disability, and up to now only
supportive therapy is available.
Patients with PPS lose more motor neurons than expected and surviving neurons fail to
maintain neurogenic supply to enlarged motor units. New data report an increased level of
inflammatory cytokines in the cerebrospinal fluid (CSF). Immune modulating therapy like IvIg
could be an option and this pilot study is the first to investigate the clinical effect of
IvIg in PPS. In addition, levels of cytokines in CSF and serum before and after treatment
will be investigated.
Minimum age: N/A.
Maximum age: 75 Months.
Post-polio syndrome diagnosed at Dept of Neurology, Haukeland University Hospital Walking
Other autoimmune disorders Other ongoing autoimmune therapy Severe cardiopulmonary disease
IgA deficiency Previous treatment of IvIg Wheelchair dependence
Locations and Contacts
Starting date: August 2003
Ending date: July 2004
Last updated: December 12, 2005